¹û¶³Ö±²¥ÊÓƵ

WHO has recommended the use of Dengvaxia in settings of high dengue endemicity. This recommendation is based on the epidemiological evidence from clinical trials and projections on long-term safety, public health impact, and cost-effectiveness analysis from mathematical models. While the dengue vaccine is currently recommended for children aged 9 years and older, we are conducting a comparative analysis of this recommendation to the scenario where the vaccine is given to children of different ages who were already exposed and are positive for dengue antibodies. We will present the findings on the epidemiological and economic impact of these vaccination scenarios.